Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Mitsuya Website

Hiroaki Mitsuya, M.D., Ph.D.

Selected Publications

1)  Nishijima T, Takano M, Ishisaka M, Komatsu H, Gatanaga H, Kikuchi Y, Endo T, Horiba M, Kaneda S, Uchiumi H, Koibuchi T, Naito T, Yoshida M, Tachikawa N, Ueda M, Yokomaku Y, Fujii T, Higasa S, Takada K, Yamamoto M, Matsushita S, Tateyama M, Tanabe Y, Mitsuya H, Oka S.
Abacavir/Lamivudine versus Tenofovir/Emtricitabine with Atazanavir/Ritonavir for Treatment-naive Japanese Patients with HIV-1 Infection: A Randomized Multicenter Trial.
Intern. Med. 52: 735-44, 2013.
[Journal]
2)  Amano M, Tojo Y, Salcedo-Gómez PM, Campbell JR, Das D, Aoki M, Xu CX, Rao KV, Ghosh AK, Mitsuya H.
GRL-0519, a Novel Oxatricyclic Ligand-Containing Nonpeptidic HIV-1 Protease Inhibitor (PI), Potently Suppresses Replication of a Wide Spectrum of Multi-PI-Resistant HIV-1 Variants In Vitro.
Antimicrob. Agents Chemother. 57: 2036-46, 2013.
[Journal]
3)  Fujiwara S, Kawano Y, Yuki H, Okuno Y, Nosaka K, Mitsuya H, Hata H.
PDK1 inhibition is a novel therapeutic target in multiple myeloma.
Br. J. Cancer. 108: 170-8, 2013.
[Journal]
4)  Yuki H, Ueno S, Tatetsu H, Niiro H, Iino T, Endo S, Kawano Y, Komohara Y, Takeya M, Hata H, Okada S, Watanabe T, Akashi K, Mitsuya H, Okuno Y.
PU.1 is a potent tumor suppressor in classical Hodgkin lymphoma cells.
Blood. 121: 962-70, 2013.
[Journal]
5)  Sohl CD, Kasiviswanathan R, Kim J, Pradere U, Schinazi RF, Copeland WC, Mitsuya H, Baba M, Anderson KS.
Balancing antiviral potency and host toxicity: identifying a nucleotide inhibitor with an optimal kinetic phenotype for HIV-1 reverse transcriptase.
Mol. Pharmacol. 82: 125-33, 2012.
[Journal]
6)  Ndongwe TP, Adedeji AO, Michailidis E, Ong YT, Hachiya A, Marchand B, Ryan EM, Rai DK, Kirby KA, Whatley AS, Burke DH, Johnson M, Ding S, Zheng YM, Liu SL, Kodama E, Delviks-Frankenberry KA, Pathak VK, Mitsuya H, Parniak MA, Singh K, Sarafianos SG.
Biochemical, inhibition and inhibitor resistance studies of xenotropic murine leukemia virus-related virus reverse transcriptase.
Nucleic Acids Res. 40: 345-59, 2012.
[Journal]
7)  Maeda K, Das D, Nakata H, Mitsuya H.
CCR5 inhibitors: emergence, success, and challenges.
Expert Opin Emerg Drugs. 17: 135-45, 2012.
[Journal]
8)  Edwards CK, Green JS, Volk HD, Schiff M, Kotzin BL, Mitsuya H, Kawaguchi T, Sakata KM, Cheronis J, Trollinger D, Bankaitis-Davis D, Dinarello CA, Norris DA, Bevilacqua MP, Fujita M, Burmester GR.
Combined anti-tumor necrosis factor-a therapy and DMARD therapy in rheumatoid arthritis patients reduces inflammatory gene expression in whole blood compared to DMARD therapy alone.
Front Immunol. 3: 366, 2012.
[Journal]
9)  Michailidis E, Singh K, Ryan EM, Hachiya A, Ong YT, Kirby KA, Marchand B, Kodama EN, Mitsuya H, Parniak MA, Sarafianos SG.
Effect of translocation defective reverse transcriptase inhibitors on the activity of N348I, a connection subdomain drug resistant HIV-1 reverse transcriptase mutant.
Cell. Mol. Biol. (Noisy-le-grand). 58: 187-95, 2012.
[Journal]
10)  Ghosh AK, Anderson DD, Weber IT, Mitsuya H.
Enhancing protein backbone binding--a fruitful concept for combating drug-resistant HIV.
Angew. Chem. Int. Ed. Engl. 51: 1778-802, 2012.
[Journal]
Click Here to View Expanded Bibliography.

This page was last updated on 4/19/2013.